Suppr超能文献

晚期乳腺癌的新型细胞毒性药物及治疗方案

New cytotoxic agents and schedules for advanced breast cancer.

作者信息

Burstein H J, Bunnell C A, Winer E P

机构信息

Department of Adult Oncology, Dana-Farber Cancer Institute, Department of Medicine, Brigham & Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.

出版信息

Semin Oncol. 2001 Aug;28(4):344-58. doi: 10.1016/s0093-7754(01)90129-0.

Abstract

Cytotoxic chemotherapy is important for treatment of women with hormone-insensitive or hormone-refractory advanced breast cancer. A variety of agents are effective, alone or in combination. The clinical activity and side effects of many agents, as well as principles for use of chemotherapy, are reviewed. Recent advances in chemotherapy for breast cancer include important studies on the role of dose-intensity, modifications of available agents to reduce side effects, and the availability of oral chemotherapeutics. Finally, the combination of chemotherapy with novel biological agents may improve outcomes for women with certain types of breast cancer. The growing availability of such biological therapies given in combination with chemotherapy may mean better survival in the future for women with advanced breast cancer.

摘要

细胞毒性化疗对于治疗激素不敏感或激素难治性晚期乳腺癌女性患者很重要。多种药物单独使用或联合使用均有效。本文综述了许多药物的临床活性和副作用,以及化疗的使用原则。乳腺癌化疗的最新进展包括关于剂量强度作用的重要研究、对现有药物进行改良以减少副作用,以及口服化疗药物的可获得性。最后,化疗与新型生物制剂联合使用可能会改善某些类型乳腺癌女性患者的治疗结果。越来越多的此类生物疗法与化疗联合使用,可能意味着晚期乳腺癌女性患者未来的生存率会提高。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验